E35A6AA5-331F-489B-8CE1-9D0BC4CDE119
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.4967148488830486
- age_years
- 26
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.558
- NOTCH_SIGNALING+0.529
- G2M_CHECKPOINT+0.462
- E2F_TARGETS+0.422
- INTERFERON_GAMMA_RESPONSE+0.403
- MITOTIC_SPINDLE+0.374
- TGF_BETA_SIGNALING+0.370
- WNT_BETA_CATENIN_SIGNALING+0.363
- MYC_TARGETS_V1+0.354
- MYC_TARGETS_V2+0.288
Top 10 suppressed
- MYOGENESIS-0.410
- KRAS_SIGNALING_DN-0.338
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.287
- PANCREAS_BETA_CELLS-0.232
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.222
- SPERMATOGENESIS-0.220
- OXIDATIVE_PHOSPHORYLATION-0.193
- HYPOXIA-0.182
- ESTROGEN_RESPONSE_LATE-0.169
- COAGULATION-0.161
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934865 | — | — | 0.927 |
| 2 | SRR934808 | — | — | 0.916 |
| 3 | 9EE765BF-748F-41B9-926F-FFD0E8C079E3 | — | — | 0.884 |
| 4 | EFB459E3-9B6A-4020-8556-6409065823B7 | — | — | 0.883 |
| 5 | SRR934848 | — | — | 0.871 |
| 6 | C67163A8-8A5F-4398-AC65-167218B010CF | — | — | 0.871 |
| 7 | SRR934751 | — | — | 0.869 |
| 8 | BS_D7XRFE0R | Diffuse intrinsic pontine glioma | — | 0.868 |
| 9 | 7604968C-689A-458D-96BA-33B163B238F8 | — | — | 0.866 |
| 10 | SRR934775 | — | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.558 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.529 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.462 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.422 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.403 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.374 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.363 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.354 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.288 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.286 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.273 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.246 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.204 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.197 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.197 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.161 | Idelalisib | — uncovered |
| PEROXISOME | 0.155 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.152 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.146 | Idelalisib | — uncovered |